Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Dusa Pharmaceuticals's marketing partner for Latin America, Stiefel Laboratories, has received final pricing approval from the Regulatory Chamber of Medicines in Brazil, for Levulan Kerastick for Photodynamic Therapy or PDT, for the treatment of actinic keratoses.
Subscribe to our email newsletter
The market launch of Levulan PDT in Brazil is expected to follow shortly. Stiefel previously received regulatory approval for Levulan Kerastick from ANVISA (Agencia Nacional de Vigilancia Sanitaria) in 2006.
In Latin America, Stiefel has also received regulatory approval for Levulan in Argentina, Mexico, Chile and Colombia, with approvals and subsequent product launches in additional markets scheduled to follow within the next several months.
Robert Doman, president and CEO of Dusa, said: “We are very optimistic about the potential for Levulan PDT in the Brazilian marketplace and we will continue to work closely with Stiefel to bring Levulan PDT to additional Latin American countries in the coming year.”